KYPROLIS® is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy in combination with: Lenalidomide and dexamethasone; or Dexamethasone; or Daratumumab (I.V. or S.C.) and dexamethasone as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.

Please refer to the PI as approved by the IL MoH. License Holder: Amgen Europe B.V., Israel Branch.

Xgeva® is indicated for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with multiple myeloma and in adults with bone metastases from solid tumors.

Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

For full details please refer to the PI as approved by the IL MoH. License Holder: Amgen Europe B.V., Israel Branch.